BETTER FOR YOU WELLNESS, INC. Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2024-08-31..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2024-08-31..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2024-08-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2024-08-31. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2024-08-31. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 0.00 USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 69.42K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -1.50M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2024-08-31 | $0.00 | (m) | $69.42K | $-1.50M | (m) | (m) | (m) | (m) | (m) |
| 2024-05-31 | $0.00 | (m) | $242.86K | $-1.76M | (m) | (m) | (m) | (m) | (m) |
| 2024-02-28 | $0.00 | (m) | $627.40K | $-2.24M | (m) | (m) | (m) | (m) | (m) |
| 2023-11-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-08-31 | (m) | (m) | $1.68M | $-2.86M | (m) | (m) | (m) | (m) | (m) |
| 2023-05-31 | (m) | (m) | $1.74M | $-3.08M | (m) | (m) | (m) | (m) | (m) |
| 2023-02-28 | $0.00 | (m) | $2.12M | $-3.34M | (m) | (m) | (m) | (m) | (m) |
| 2022-11-30 | (m) | (m) | $1.98M | $-3.04M | (m) | (m) | (m) | (m) | (m) |
| 2022-08-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-05-31 | (m) | (m) | $2.83M | $-3.44M | (m) | (m) | (m) | (m) | (m) |
| 2022-02-28 | $0.00 | (m) | $2.07M | $-2.54M | (m) | (m) | (m) | (m) | (m) |
| 2021-11-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-08-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-05-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.